Amniotic-like Epithelial Cell Generation via Pathway Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating and expanding human amniotic epithelial cells in vitro are limited, leading to a need for improved sources and methods to produce these cells, which are desirable for regenerative medicine due to their low immunogenicity and anti-inflammatory properties, but face challenges such as regional restrictions and risks of infectious disease transmission from placental material.
Innovation Solution
A method involving the differentiation of pluripotent stem cells into amniotic-like epithelial cells by culturing them with inhibitors of the MAPK and TGF pathways, allowing for the recapitulation of developmental events and the establishment of a robust source of amniotic-like epithelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amniotic epithelial cells are extracted from term placenta, then the cells possess low immunogenicity and anti-inflammatory properties, but there are regional restrictions on clinical use and risks of infectious disease transmission
Solution Approach 1:
The patent creates a copy of amniotic epithelial cells by differentiating pluripotent stem cells into amniotic-like epithelial cells through controlled culture conditions. This copying approach allows obtaining cells with the desired therapeutic properties without using actual placental material, thereby eliminating infectious disease transmission risks while maintaining low immunogenicity and anti-inflammatory characteristics
Solution Approach 2:
The patent uses pluripotent stem cells as an intermediary to generate amniotic-like epithelial cells. These stem cells serve as a safe intermediate source that can be differentiated into target cells under controlled conditions, avoiding direct use of placental material and its associated risks while still producing cells with the required therapeutic properties
2Productivity
If current methods are used to expand amniotic epithelial cells in vitro, then the cells can be obtained for therapeutic use, but the expansion capability is very limited
Solution Approach 1:
The patent changes key culture parameters by using specific small molecule inhibitors (PD0325901 for MAPK pathway and A8301 for TGFβ pathway) to control cell differentiation and expansion. This parameter modification enables robust in vitro expansion of amniotic-like epithelial cells from pluripotent stem cells, overcoming the limited expansion capability of conventional methods
Solution Approach 2:
The patent replaces complex mechanical or manual cell expansion methods with a chemically-controlled differentiation system using small molecule inhibitors. This substitution simplifies the overall process by using well-defined chemical agents to control cell fate and proliferation, enabling scalable production without excessive procedural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the efficient production of amniotic-like epithelial cells that form continuous layers or 3D structures, expressing characteristic markers and possessing therapeutic potential for regenerative medicine and research, while minimizing the risks associated with placental-derived cells.
Implementation Method 1
differentiating pluripotent stem cells into amniotic-like epithelial cells by culturing them with inhibitors of the MAPK and TGF pathways
Data Source
AI summary
The present invention relates to a reliable method for producing amniotic-like epithelial cells, using a new methodology. The invention also relates to a composition and the use of said composition comprising amniotic-like epithelial cells or a preparation derived therefrom. Said cells may have particular utility in regenerative medicine, research and/or cosmetic preparations.